Table 3. Changes in the CCS and 15D from baseline to 12 months follow-up by subgroups.
The values are n (%).
| Treatment group | Age group | Gender | Total | |||||
|---|---|---|---|---|---|---|---|---|
| OMT | CABG | PCI | <70 | ≥70 | male | female | ||
| Change in CCS | n = 365 | n = 169 | n = 280 | n = 425 | n = 389 | n = 534 | n = 280 | n = 814 (100%) |
| (≥2, deterioration) 1 | 5 (1.4%) | 0 (0.0%) | 6 (2.1%) | 6 (1.4%) | 5 (1.3%) | 6 (1.1%) | 5 (1.8%) | 11 (1.4%) |
| (1) 2 | 22 (6.0%) | 8 (4.8%) | 15 (5.4%) | 25 (5.9%) | 20 (5.1%) | 30 (5.6%) | 15 (5.4%) | 45 (5.5%) |
| (0, no change) 3 | 208 (57.0%) | 61 (36.1%) | 139 (49.6%) | 200 (47.1%) | 208 (53.5%) | 255 (47.8%) | 153 (54.6%) | 408 (50.1%) |
| (-1) 4 | 95 (26.0%) | 87 (51.5%) | 99 (35.4%) | 150 (35.3%) | 131 (33.7%) | 199 (37.3%) | 82 (29.3%) | 281 (34.5%) |
| (≤-2, improvement) 5 | 35 (9.6%) | 13 (7.7%) | 21 (7.5%) | 44 (10.4%) | 25 (6.4%) | 44 (8.2%) | 25 (8.9%) | 69 (8.5%) |
| Missing values | n = 457 | |||||||
| Change in 15D a | n = 387 | n = 173 | n = 292 | n = 441 | n = 411 | n = 554 | n = 298 | n = 852 (100%) |
| (much worse) 1 | 107 (27.6%) | 27 (15.6%) | 58 (19.9%) | 93 (21.1%) | 99 (24.1%) | 128 (23.1%) | 64 (21.5%) | 192 (22.5%) |
| (slightly worse) 2 | 45 (11.6%) | 13 (7.5%) | 31 (10.6%) | 42 (9.5%) | 47 (11.4%) | 55 (9.9%) | 34 (11.4%) | 89 (10.4%) |
| (no change) 3 | 87 (22.5%) | 27 (15.6%) | 55 (18.8%) | 94 (21.3%) | 75 (18.2%) | 100 (18.1%) | 69 (23.2%) | 169 (19.8%) |
| (slightly better) 4 | 54 (14.0%) | 16 (9.2%) | 44 (15.1%) | 48 (10.9%) | 66 (16.1%) | 76 (13.7%) | 38 (12.7%) | 114 (13.4%) |
| (much better) 5 | 94 (24.3%) | 90 (52.0%) | 104 (35.6%) | 164 (37.2%) | 124 (30.2%) | 195 (35.2%) | 93 (31.2%) | 288 (33.8%) |
| Missing values | n = 419 | |||||||
aBased on the reported minimal important difference (MID) for the instrument [24].